Covid-19 therapy with monoclonal antibodies




Covid-19; Monoclonal Antibody; Immunotherapy.


In December 2019, in the city of Wuhan, a new viral variant emerged causing an outbreak of respiratory syndrome of unknown origin. In parallel with this, several effective vaccines have been developed, as well as studies of drug candidates capable of limiting and preventing the replication of the virus are underway. This review aims to investigate in the scientific literature the use of possible treatment strategies of monoclonal antibodies against SARS-CoV-2 infection. A systematic review of the literature available in the PubMed, Scielo and ScienceDirect databases was carried out, using as descriptors: covid-19, monoclonal antibodies and immunotherapy published in Portuguese, English and Spanish, with a range from 2020 to 2022. Of the 638 studies found, 17 were selected. Neutralizing monoclonal antibody therapies targeting SARS-CoV-2 were considered promising potential therapies for Covid-19, belonging to different pharmacological classes such as spike protein inhibitors, IL-6 inhibitors, IL-1-β inhibitors, ACE2 inhibitors, NAMP neutralizers, anti-granulocyte-macrophage stimulating factor, anti-CD6 IgG1, but its large-scale production for clinical application is laborious, expensive and costly. In this way, the advances in immunotherapeutic treatments are notable, but it is also necessary to design and develop advanced protein production platforms in order to provide efficient monoclonal antibodies at an affordable cost in a short time.


Baral, P. K., Yin, J. & James, N. G. (2021). Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. International Journal of Biological Macromolecules. 186(1), 490-500.

Bayat, M., Asemani, A., Mohammandi, M. R. & Sanei, M. (2021). An overview of some potential immunotherapeutic options against COVID-19. International Immunopharmacology. 95. 107516.

Both, L., Ashkey, C., Banyard, C. D., Wright, E., Ma, J. K. C., & Fooks, A. R. (2013). Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Vaccine. 31. 1553-1559.

Cavalcante, J. R., Cardoso-dos-Santos, A. C., Bremm, J. M., Lobo, A. P., Macário, E. M., Oliveira, W. K., & França, G. V. A. (2020). COVID-19 in Brazil: evolution of the epidemic up until epidemiological week 20 of 2020. Epidemiologia e Serviços de Saúde. 29(4), 1-13.

Cohen, M. S., Nirula, A., Mulligan, M. J., Novak, R. M., Marovich, M., Yen, C., Stemer, A., Mayer, S. M., Wohl, D., & Brengle, B. (2021). Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities. Jama. 326(1), 46–55.

Deb, P., Maruf, Md., Molla, A., & Saif-ur-rahman, K. M. (2021). An update to monoclonal antibody as therapeutic option against COVID-19. Biosafety and Health. v. 3, 87-91.

Fisher, B., Veenith, T., Slade, D., Gaskell, C., Rowland, M., Whitehouse, T., Scriven, J., Parekh, D., Balasubramaniam, M., & Cooke, G. (2022). Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. The Lancet Respiratory Medicine. 10, 255-266.

Hickmann, M. F. G., Alexandre, R. C. V., Morra, R. O. G., Pereira, T. V. P., Barros, S. P. C., Neto, M. L., & Alexandre, P. C. B. (2020). Fisiopatologia da COVID-19 e alvo farmacológico tromboimunológico. Vittalle –Revista de Ciências da Saúde. 32, 30-34.

Jafari, A., & Ghasemi, S. (2020). The possible of immunotherapy for COVID-19: A systematic review. Int Immunopharmacol. v.83, 106455.

Jahanshahlu, L., & Rezaei, N. (2020). Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 129, 110337.

Liberati, A., Altman, D. G., Tetzlaffe, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Deevereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Research methods & reporting. v. 339, 2700.

Luo, L., Liu., D., Liao, X., Wu, X., Jing, Q., Zhen, J., Liu, F., Yang, s., Bi, H., Li, Z., Liu, J., Song, W., Zhu, W., Wang, Z., Zhang, X., Huang, Q., Chen, P., Liu, H., Cheng, X., Cai, M., Yang, P., Yang, X., Han, Z., Tang, J., Ma, Y., & Mao, C. (2020). Modes of Contact and Risk of Transmission in COVID-19. A Prospectiva Cohort Study 4950 Close Contact Persons in Guangzhou of China. Ann Intern Med. V. 73(11), 879-887.

Kang, L., Li, Y., Hu, S., Chein, M., Yang C., Yang, B. X., Wang, Y., Hu, J., Lai, J., Ma, X., Chen, J., Guan, L., Wang, G., Ma, H., & Liu, Z. (2020). The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. The Lancet Psychiatry. 7, 3-14.

Kumar, S., Souza, R., Nadkar, M., Guleria, R., Trikha, A., Joshi, S. R., Loganathan, S., Vaidyanathan, S., Marwah, A., & Athalye, S. N. (2021). A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opinion On Biological Therapy. 21, 675-686.

Majidpoor, J. & Mortezaee, K. (2022). Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomedicine & Pharmacotherapy. v. 145, 112419.

Masoomikarimi, M., Garmabi, B., Alizadeh, J., Kazemi, E., Jafari, A. A., Mirmoeeni, S., Dargahi, M., Taheri, N., & Jafari, R. (2021). Advances in immunotherapy for COVID-19: a comprehensive review. Imunofarmacologia Internacional. 93, 107409.

Mendes, K. D. S., Silveira, R. C. C. P., & Galvão, C.M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto Enfermagem. v. 17(4), 758-64.

Organização Mundial Da Saúde. (2022). WHO Coronavirus (COVID-19) Dashboard.

Owji, H., Negahdaripour, M., & Hajughahram, A. (2020) Immunotherapeutic approaches to curtail COVID-19. International Immunopharmacology. v. 88, 106924.

Patel, S., Saxena, B., & Mehta, P. (2021). Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. European Journal of Medical Research. v. 7, 1-15.

Rogers, C. J., Harman, R. J., Bunneell, B. A., Schreiber, M. A., Xiang, C., Wang, F. S., Santidrian, A. F., & Mineyi, B. R. (2020). Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. Journal of translational medicine, 18(1), 203.

Salvati, L., Occhipinti, M., Gori, L., Ciani, L., Mazzoni, A., Maggi, L., Capone, M., Parronchi, P., Liotta, F., Miele, V., Annuziato, F., Lavorni, F., & Cosmi, L. (2020). Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. Immunology Letters. v. 228, 122-128.

Self, W. H., Sandkovsky, U., Reilly, C. S., & Vock, D. M. (2021). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. v. 22(5), 622–35.

Silva, F. D. & Oliveira, C. M. L. (2020). Epidemiologia da COVID-19: comparação entre boletins epidemiológicos. Com. Ciências Saúde. v. 31, 61-74.

Song, Z., Xu, Y., Bao, L., Zhang, L., Yu P., Qu Y., Zhu, H., Zhao, W., Han, Y., Qin, C. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. v. 14, 11-59.

Shanmugaraj, B., Siriwattananon, K., Wangkanont, K., & Phoolcharoen, W. (2020). Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. v.38, 10-18.

Tay, M. Z., Poh, C. M., Rénia, L., Macary, P. A., Ng, L. F. P. (2020). The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology. v. 20, p. 363-374.

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The

PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ,

, b2700.

Vaidya, G., Czer, L. C. S., Kobashigawa, J., Kittleson, M., Patel, J., Chang, D., Kransdorf, D. C., Shikhare, A., Tran, H., Ammerman, N., Huang, E., Zabner, R., & Jordan, S. (2020). Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings. 52, 2711-2714.

Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., Zhou, Y., Zheng, X., Yang, Y., Li, X., Zhang, X., Pan, A., & Wei, H. (2020). Effective treatment of critically ill patients with COVID-19 with tocilizumab. Proceedings of the National Academy of Sciences of the United States of America. v.117 (20), 10970-10975.

Wu, Z. & Mcgoogan, J. M. (2020) Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 323(13), 1239-1242.



How to Cite

SILVA, G. G. D. da; FELÍCIO, I. M.; OLIVEIRA, L. N. de .; SANTOS, A. K. F. de S. .; MACÊDO, C. L. . Covid-19 therapy with monoclonal antibodies. Research, Society and Development, [S. l.], v. 11, n. 9, p. e20011931668, 2022. DOI: 10.33448/rsd-v11i9.31668. Disponível em: Acesso em: 19 aug. 2022.



Health Sciences